How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/loteprednol-etabonate-tobramycin-opthalmic-suspension.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

loteprednol etabonate/tobramycin opthalmic suspension — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

loteprednol etabonate/tobramycin opthalmic suspension (loteprednol etabonate/tobramycin opthalmic suspension) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Corticosteroid/Aminoglycoside antibiotic combination. Area: Ophthalmology.

marketed Corticosteroid/Aminoglycoside antibiotic combination Glucocorticoid receptor (loteprednol); bacterial ribosome 30S subunit (tobramycin) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

loteprednol etabonate/tobramycin opthalmic suspension (loteprednol etabonate/tobramycin opthalmic suspension) — Bausch & Lomb Incorporated. Loteprednol etabonate reduces ocular inflammation via glucocorticoid receptor activation, while tobramycin provides broad-spectrum bacterial coverage by inhibiting bacterial protein synthesis.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
loteprednol etabonate/tobramycin opthalmic suspension TARGET	loteprednol etabonate/tobramycin opthalmic suspension	Bausch & Lomb Incorporated	marketed	Corticosteroid/Aminoglycoside antibiotic combination	Glucocorticoid receptor (loteprednol); bacterial ribosome 30S subunit (tobramycin)
Loteprednol/tobramycin	Loteprednol/tobramycin	Massachusetts Eye and Ear Infirmary	marketed	Corticosteroid/aminoglycoside antibiotic combination	Glucocorticoid receptor (loteprednol); bacterial 30S ribosome (tobramycin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Corticosteroid/Aminoglycoside antibiotic combination class)

Bausch & Lomb Incorporated · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). loteprednol etabonate/tobramycin opthalmic suspension — Competitive Intelligence Brief. https://druglandscape.com/ci/loteprednol-etabonate-tobramycin-opthalmic-suspension. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab